BRIEF-Cue Biopharma Appoints New CEO, Shifts Focus to Autoimmune Therapies Sept 29 (Reuters) - Cue Biopharma Inc CUE.O:
CUE BIOPHARMA ANNOUNCES STRATEGIC TRANSITION IN LEADERSHIP TO FURTHER ENABLE NEXT STAGE OF GROWTH WITH DISRUPTIVE AUTOIMMUNE THERAPEUTIC CANDIDATES
CUE BIOPHARMA INC - USMAN AZAM APPOINTED CEO OF CUE BIOPHARMA
CUE BIOPHARMA INC - DANIEL PASSERI TRANSITIONS TO STRATEGIC ADVISOR AT CO
Source text: ID:nGNX7tqC0T
Further company coverage: CUE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments